Terray Therapeutics announced it has achieved a discovery milestone under its multi‑target collaboration with Bristol Myers Squibb, validating its Experimentation Meets Machine Intelligence (EMMI) platform’s ability to identify small molecules against a novel, difficult target. The milestone underscores Terray’s tArray hardware and large binding dataset as core assets for generalizing discovery beyond existing chemical space. Terray says its tArray hardware generates binding affinity measurements at an industrial scale, producing training data for AI models that aim to propose novel chemotypes. The company highlighted a milestone payment under the BMS collaboration and described the target as representative of difficult-to‑drug proteins. The development reinforces demand from big pharma for data‑driven discovery partners that can offer high‑throughput experimental datasets and AI models, while preserving downstream development and commercialization rights for the pharma partner.